I see that CRDF, Cardiff Oncology Inc., had a .56
Post# of 126761
(Total Views: 153)
Posted On: 08/25/2021 4:53:45 PM
Re: wowhappens28 #68167
I see that CRDF, Cardiff Oncology Inc., had a .56 gain today which left them with a hellacious pps of 6.66. LOL
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer, Resistant Metastatic Castration-Resistant Prostate Cancer and relapsed or refractory Acute Myeloid Leukemia. Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.
https://cardiffoncology.com/
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer, Resistant Metastatic Castration-Resistant Prostate Cancer and relapsed or refractory Acute Myeloid Leukemia. Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.
https://cardiffoncology.com/
(0)
(0)